Pedmark Approval Status
FDA Approved: No
Brand name: Pedmark
Generic name: sodium thiosulfate
Company: Fennec Pharmaceuticals Inc.
Treatment for: Prevention of Cisplatin-Induced Ototoxicity
Pedmark (sodium thiosulfate) is a cisplatin neutralizing agent in development for the protection against hearing loss in pediatric patients receiving cisplatin chemotherapy.
Development Status and FDA Approval Process for Pedmark
|Dec 20, 2018||Fennec Pharmaceuticals Initiates Rolling New Drug Application to FDA for Pedmark|
|Mar 22, 2018||Fennec Pharmaceuticals Receives Fast Track Designation by FDA for Pedmark|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.